Evidence map›Paper›PMID 41812711›Full record

Trial reportJournal of pain and symptom management2026

Results of a Randomized Phase 2 Trial of One Versus Two 8 Gy Fractions for Painful Bone Metastases.

Ryan T Hughes, Sydney Smith, Bart A Frizzell, Michael K Farris, Heather D Pacholke, Christina K Cramer, Michael D Chan, Laura F Allen, Ralph B D'Agostino, Jeffrey S Willey and 4 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Journal of pain and symptom management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ryan T HughesDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA. Electronic address: ryan.t.hughes@wfusm.edu.
Sydney SmithDepartment of Biostatistics and Data Science (S.S., R.B.A.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Bart A FrizzellDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Michael K FarrisDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Heather D PacholkeDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA; Department of Radiation Oncology (H.D.P., L.F.A.), Atrium Health Wake Forest Baptist Hayworth Cancer Center, High Point, North Carolina, USA.
Christina K CramerDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Michael D ChanDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Laura F AllenDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA; Department of Radiation Oncology (H.D.P., L.F.A.), Atrium Health Wake Forest Baptist Hayworth Cancer Center, High Point, North Carolina, USA.
Ralph B D'AgostinoDepartment of Biostatistics and Data Science (S.S., R.B.A.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Jeffrey S WilleyDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Sun H ParkDepartment of Anesthesiology (S.H.P., E.A.R-S.), Wake Forest University School of Medicine, Winston Salem NC, USA.
E Alfonso Romero-SandovalDepartment of Anesthesiology (S.H.P., E.A.R-S.), Wake Forest University School of Medicine, Winston Salem NC, USA.
Brian E LallyDepartment of Radiation Oncology (B.L.), Medical University of South Carolina, Charleston, SC, USA.
Doris R BrownDepartment of Radiation Oncology (R.T.H., B.A.F., M.K.F., H.D.P., C.K.C., M.D.C., L.F.A., J.S.W., D.R.B.), Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

contextSingle-fraction 8 Gy palliative radiotherapy (RT) is a standard regimen for the relief of painful bone metastases. However, the delivery of single-fraction RT may result in higher retreatment rates compared to longer courses.

objectivesTo compare 6‑month retreatment rates after 8 Gy x 1 versus 8 Gy x 2 and evaluate pain response, quality of life, and adverse events (AEs).

methodsIn this prospective, randomized, multi-center phase 2 trial, adults with painful bone metastases were randomized to 8 Gy x 1 (arm 1) or 8 Gy x 2 (arm 2). The primary endpoint was the 6-month cumulative incidence of retreatment, with death as a competing risk. Secondary endpoints included pain response, adverse events, and quality of life using multiple patient-reported outcome measures.

resultsA total of 102 patients were randomized and treated (51 per arm). The 6-month retreatment rates were 11.5% in arm 1 v. 10.3% in arm 2 (p = 1.00). The cause-specific hazard ratio of retreatment in arm 2 (v. arm 1) was 0.87 (p = .83). Rates of death without retreatment at 6-months were 23.3% and 29.4%, respectively. Pain response rates at 3 months were similar between arms: 55% v. 72% in arms 1 v. 2, respectively (p = .20). No substantial differences in QOL were observed between groups. Grade 2+ AEs occurred in 13.7% and 15.7% (p = .78).

conclusionNo differences were observed in retreatment rates, pain response, or QOL between 8 Gy x 1 and 8 Gy x 2. Single-fraction palliative RT remains a standard for patients with painful bone metastases.

Indexed as

Bone NeoplasmsCancer PainPainPalliative CareAdultAgedDose Fractionation, RadiationFemaleHumansMaleMiddle AgedPain MeasurementProspective StudiesQuality of LifeRetreatmentTreatment Outcomepain managementpalliative treatmentRadiotherapy

Identifiers

PMID41812711
PMCPMC13242097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.